BioSpace News Archive

Taiwan Liposome Company, Ltd. today announced that it will feature a poster presentation covering the complete dataset from its Phase I/II study of the company’s lead product candidate, TLC599, in patients with knee osteoarthritis at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR),

Bruker Corporation (NASDAQ: BRKR) announced today it will present at the 16th Annual Morgan Stanley Global Healthcare Conference.

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16th Annual Morgan Stanley Global Healthcare Conference in New York next week.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company’s fourth quarter of fiscal year 2018

Technavio analysts forecast the global diabetic foot ulcers market to grow at a CAGR of over 11% during the forecast period, according to their latest market research report.

Genomic Health, Inc., (NASDAQ: GHDX) today announced the publication of an updated assessment of breast cancer gene expression profiling tests by the German Institute for Quality and Efficiency in Health Care (IQWiG)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to present at the Morgan Stanley 16th Annual Global Healthcare Conference in New York on Sept. 12, 2018 at 3:40 p.m. EDT.

Technavio analysts forecast the global disposable blood pressure cuffs market to grow at a CAGR of over 11% during the forecast period, according to their latest market research report

Pharma Mar, S.A. (MCE: PHM) (“Pharma Mar” or the “Company”) is announcing its intention to conduct a registered public offering of American Depositary Shares representing its shares in the United States.

Rafael Holdings, Inc. (NYSE American: RFL) today announced that, through a subsidiary, it has partially exercised a warrant to purchase preferred equity in Rafael Pharmaceuticals, Inc (“Rafael Pharma”), a clinical stage, metabolic oncology-therapeutics company which is developing innovative, highly selective and well tolerated anti-cancer agents.